Changes in store for early-stage non-small cell lung cancer

Jason E. Sandler, Angelica D'Aiello, Balazs Halmos

Research output: Contribution to journalReview article

Abstract

The management of advanced non-small cell lung cancer (NSCLC) has been revolutionized in recent years with the introduction of biomarker-targeted molecular therapies and immune checkpoint inhibitors. In contrast, since adjuvant chemotherapy was first established twenty years ago as the standard of care, little has changed for resected early-stage (IB-IIIA) patients for whom the potential for cure is greatest. In this manuscript we will review recently presented data as well as ongoing/planned studies in this arena. So far, investigative efforts have yielded mixed results regarding the use of tyrosine kinase inhibitors (TKIs) in early-stage NSCLC, though a series of now better planned, biomarker-driven ongoing phase III trials may be more informative. Several innovative immunotherapy studies have already shown promising results principally in the neoadjuvant setting with a large number of pivotal neo-adjuvant and adjuvant trials now in progress. Given the more robust design and biomarker-focused approach of the new generation of studies, significant advances in the optimal curative treatment of early stage NSCLC are anticipated.

Original languageEnglish (US)
Pages (from-to)2117-2125
Number of pages9
JournalJournal of Thoracic Disease
Volume11
Issue number5
DOIs
StatePublished - Jan 1 2019

Fingerprint

Non-Small Cell Lung Carcinoma
Biomarkers
Molecular Targeted Therapy
Adjuvant Chemotherapy
Standard of Care
Protein-Tyrosine Kinases
Immunotherapy
Therapeutics

Keywords

  • Adjuvant therapy
  • Immunotherapy
  • Lung cancer
  • Neoadjuvant therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Changes in store for early-stage non-small cell lung cancer. / Sandler, Jason E.; D'Aiello, Angelica; Halmos, Balazs.

In: Journal of Thoracic Disease, Vol. 11, No. 5, 01.01.2019, p. 2117-2125.

Research output: Contribution to journalReview article

Sandler, Jason E. ; D'Aiello, Angelica ; Halmos, Balazs. / Changes in store for early-stage non-small cell lung cancer. In: Journal of Thoracic Disease. 2019 ; Vol. 11, No. 5. pp. 2117-2125.
@article{79450b1d76f04599a21ffbbe822373a0,
title = "Changes in store for early-stage non-small cell lung cancer",
abstract = "The management of advanced non-small cell lung cancer (NSCLC) has been revolutionized in recent years with the introduction of biomarker-targeted molecular therapies and immune checkpoint inhibitors. In contrast, since adjuvant chemotherapy was first established twenty years ago as the standard of care, little has changed for resected early-stage (IB-IIIA) patients for whom the potential for cure is greatest. In this manuscript we will review recently presented data as well as ongoing/planned studies in this arena. So far, investigative efforts have yielded mixed results regarding the use of tyrosine kinase inhibitors (TKIs) in early-stage NSCLC, though a series of now better planned, biomarker-driven ongoing phase III trials may be more informative. Several innovative immunotherapy studies have already shown promising results principally in the neoadjuvant setting with a large number of pivotal neo-adjuvant and adjuvant trials now in progress. Given the more robust design and biomarker-focused approach of the new generation of studies, significant advances in the optimal curative treatment of early stage NSCLC are anticipated.",
keywords = "Adjuvant therapy, Immunotherapy, Lung cancer, Neoadjuvant therapy",
author = "Sandler, {Jason E.} and Angelica D'Aiello and Balazs Halmos",
year = "2019",
month = "1",
day = "1",
doi = "10.21037/jtd.2019.05.34",
language = "English (US)",
volume = "11",
pages = "2117--2125",
journal = "Journal of Thoracic Disease",
issn = "2072-1439",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "5",

}

TY - JOUR

T1 - Changes in store for early-stage non-small cell lung cancer

AU - Sandler, Jason E.

AU - D'Aiello, Angelica

AU - Halmos, Balazs

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The management of advanced non-small cell lung cancer (NSCLC) has been revolutionized in recent years with the introduction of biomarker-targeted molecular therapies and immune checkpoint inhibitors. In contrast, since adjuvant chemotherapy was first established twenty years ago as the standard of care, little has changed for resected early-stage (IB-IIIA) patients for whom the potential for cure is greatest. In this manuscript we will review recently presented data as well as ongoing/planned studies in this arena. So far, investigative efforts have yielded mixed results regarding the use of tyrosine kinase inhibitors (TKIs) in early-stage NSCLC, though a series of now better planned, biomarker-driven ongoing phase III trials may be more informative. Several innovative immunotherapy studies have already shown promising results principally in the neoadjuvant setting with a large number of pivotal neo-adjuvant and adjuvant trials now in progress. Given the more robust design and biomarker-focused approach of the new generation of studies, significant advances in the optimal curative treatment of early stage NSCLC are anticipated.

AB - The management of advanced non-small cell lung cancer (NSCLC) has been revolutionized in recent years with the introduction of biomarker-targeted molecular therapies and immune checkpoint inhibitors. In contrast, since adjuvant chemotherapy was first established twenty years ago as the standard of care, little has changed for resected early-stage (IB-IIIA) patients for whom the potential for cure is greatest. In this manuscript we will review recently presented data as well as ongoing/planned studies in this arena. So far, investigative efforts have yielded mixed results regarding the use of tyrosine kinase inhibitors (TKIs) in early-stage NSCLC, though a series of now better planned, biomarker-driven ongoing phase III trials may be more informative. Several innovative immunotherapy studies have already shown promising results principally in the neoadjuvant setting with a large number of pivotal neo-adjuvant and adjuvant trials now in progress. Given the more robust design and biomarker-focused approach of the new generation of studies, significant advances in the optimal curative treatment of early stage NSCLC are anticipated.

KW - Adjuvant therapy

KW - Immunotherapy

KW - Lung cancer

KW - Neoadjuvant therapy

UR - http://www.scopus.com/inward/record.url?scp=85067092310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067092310&partnerID=8YFLogxK

U2 - 10.21037/jtd.2019.05.34

DO - 10.21037/jtd.2019.05.34

M3 - Review article

VL - 11

SP - 2117

EP - 2125

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

SN - 2072-1439

IS - 5

ER -